Engineering An AAV Platform For Superior Titer And Capsid Integrity

As the demand for gene therapies grows, there’s a critical need for scalable, cost-effective manufacturing processes that ensure high viral vector titers and a high percentage of full capsids. This on-demand webinar introduces a powerful transfection reagent and enhancer platform—featuring the TransIT-VirusGEN® Transfection Reagent and RevIT™ AAV Enhancer—which can increase AAV titers and percent full capsids by 2- to 10-fold, independent of serotype, media, or HEK suspension cell type.

Through real-world data from CDMO Recipharm, attendees will see how these tools enhance manufacturing efficiency, reduce costs per bioreactor run, and drive down the cost per patient dose. Key discussion points include the optimization of AAV production across various serotypes, Recipharm’s approach to developing scalable viral vector manufacturing processes, and how these innovations improve access to therapies for patients.

Gain actionable insights into advanced upstream process development and explore how these strategies can meet today’s gene therapy manufacturing challenges. Access the webinar now to discover how you can enhance your AAV platform for higher titers and more full capsids.